Oren Livnat
Stock Analyst at HC Wainwright & Co.
(4.60)
# 229
Out of 5,055 analysts
140
Total ratings
54.07%
Success rate
28.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $23.78 | +173.34% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $3.93 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $46.01 | +8.67% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $11.37 | +9.94% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $84.03 | +11.86% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $8.88 | +125.23% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $141.07 | +53.82% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $7.18 | +11.42% | 11 | Mar 7, 2025 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $21 | $23.56 | -10.87% | 16 | Mar 4, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $72.92 | +0.11% | 9 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.06 | +292.16% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $5.06 | +48.22% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $0.59 | +1,265.65% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $2.87 | +1,973.17% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $0.37 | +52,784.62% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $23.78
Upside: +173.34%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $3.93
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $46.01
Upside: +8.67%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $11.37
Upside: +9.94%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $84.03
Upside: +11.86%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $8.88
Upside: +125.23%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $141.07
Upside: +53.82%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $7.18
Upside: +11.42%
Avadel Pharmaceuticals
Mar 4, 2025
Reiterates: Buy
Price Target: $21
Current: $23.56
Upside: -10.87%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $72.92
Upside: +0.11%
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $3.06
Upside: +292.16%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $5.06
Upside: +48.22%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $0.59
Upside: +1,265.65%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $2.87
Upside: +1,973.17%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $0.37
Upside: +52,784.62%